# Combination Therapy of F16IL2 and Doxorubicin in Solid Tumour Patients

> **NCT01131364** · PHASE1,PHASE2 · TERMINATED · sponsor: **Philogen S.p.A.** · enrollment: 29 (actual)

## Conditions studied

- Advanced Solid Tumor
- Breast Cancer

## Interventions

- **DRUG:** F16IL2 in combination with doxorubicin

## Key facts

- **NCT ID:** NCT01131364
- **Lead sponsor:** Philogen S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-06
- **Primary completion:** 2012-03
- **Final completion:** 2012-12
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2014-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01131364

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01131364, "Combination Therapy of F16IL2 and Doxorubicin in Solid Tumour Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01131364. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*